Showing results (71-80 of 92) with videos related to
Sort By:
Pageof 10
Environmental Epigenetics|May 27, 2026
DNA methylation mediates the multiple sclerosis onset risk associated with HHV-6 DNA positivityAlex Eisner, Steve Simpson-Yap, Daniel J Park, et al.Plos One|December 15, 2010
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosisCarlos Riveros, Drew Mellor, Kaushal S Gandhi, et al.Journal of Neurology|July 3, 2024
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysisSimon Arnett, Sin Hong Chew, Unnah Leitner, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2024
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapseBenjamin P Trewin, Russell C Dale, Jessica Qiu, et al.CNS Drugs|January 10, 2025
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic ApproachVivien Li, Fiona C McKay, David C Tscharke, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.BMJ Neurology Open|December 26, 2025
Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trialKayla Ward, Vivien Li, Sudarshini Ramanathan, et al.Pageof 10